Highlights Curis, Inc.

Equities

CRIS

US2312693094

Delayed Nasdaq Other stock markets 12:35:40 2024-05-13 EDT			5-day change	1st Jan Change
15.45 ^USD	-1.69%		-4.42%	+21.21%

05-07	Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M	05-07	MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M	02-08	MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-08	CI
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	12-12	CI
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	12-05	CI
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M	11-02	MT
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Reverse Split: 1 of 20	23-09-28	FA
Earnings Flash (CRIS) CURIS Reports Q2 Revenue $2.2M, vs. Street Est of $2.5M	23-08-03	MT
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study	23-07-06	MT
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID	23-07-06	CI
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Earnings Flash (CRIS) CURIS Posts Q4 Revenue $2.9M, vs. Street Est of $3.3M	23-03-13	MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS	22-12-12	CI
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Curis, Inc.

Equities

CRIS

US2312693094

Highlights

Filters